$25.640
-0.169 (-0.66%)At close
KMTS News
KMTS Events
Kestra Expects Revenue of $137 Million in FY27
The company said, "Kestra expects revenue of $137 million in FY27, which would represent growth of 44% compared to FY26."
Kestra Q4 Revenue Reaches $28.64M, Exceeds Expectations
Reports Q4 revenue $28.64M, consensus $26.48M. "Kestra concluded fiscal year 2026 with another strong quarter of financial performance, generating revenue growth of 66% while expanding gross margin to 55%," said Brian Webster, President and CEO. "In fiscal year 2026, the ASSURE system protected 18,000 patients from sudden cardiac arrest, a testament to the dedication of our mission-driven team. We also made significant progress on key operational objectives, including rapid growth of our commercial organization, release of compelling primary results from our FDA post-approval study, launch of our latest algorithm update, fortification of our balance sheet, and entrance into a strategic collaboration with Biobeat Technologies. We remain confident that our focus on innovation and executing on our commitments to prescribers and their patients will continue to drive market expansion and advance Kestra on its path to market leadership."
Kestra Medical Files Automatic Common Shares Offering
Kestra Medical files automatic common shares offering
Kestra Raises FY26 Revenue Guidance to $93 Million
The company said, "Kestra is increasing its FY26 revenue guidance to $93 million, which would represent growth of 55% compared to FY25. This compares to prior FY26 revenue guidance of $91 million and initial FY26 guidance of $85 million."
Kestra Reports Q3 Revenue of $24.55M, Exceeding Expectations
Reports Q3 revenue $24.55M, consensus $22.87M. "Kestra delivered another strong quarter of financial performance, generating revenue growth of 63% while expanding gross margin to over 52%," said Brian Webster, president and CEO. "We also continued to execute on several key operational objectives, including rapid growth of the commercial organization, release of compelling primary results from our FDA post-approval study, fortification of our balance sheet with an equity offering, and entrance into a strategic collaboration with Biobeat Technologies. As we progress on our journey to category leadership, our team remains focused on growing the wearable defibrillator market and executing on our commitments to patients and their prescribers."
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.